Cereno Scientific – executive interview

In this interview, we discuss with Sten Sörensen, CEO of Cereno Scientific, the recent comprehensive financing package announced by the company, which will support its upcoming Phase IIb trial for its lead asset CS1 and other development milestones into Q427. Sten highlights the premium terms of the financing and strong investor interest, as well as what this means for the company and its shareholders. Sten emphasises the importance of the upcoming Phase IIb trial for both Cereno and patients, given the unmet need in pulmonary arterial hypertension (PAH) and the lack of disease-modifying options. He outlines the upcoming catalysts and milestones for Cereno over the next 12–18 months, including more advanced-stage trials for CS1 and CS014.

Cereno Scientific (STO: CRNO-B) is a clinical-stage biotech focused on developing innovative treatments for rare indications in the cardiovascular and pulmonary spaces. Its pipeline is led by CS1 and CS014, HDAC inhibitors with disease-modifying potential in PAH and idiopathic pulmonary fibrosis (IPF), respectively. Both candidates are backed by promising clinical data and are gearing up for more advanced-stage clinical studies (Phase IIb for CS1 and Phase II for CS014) in H126. A third asset, CS585, a prostacyclin receptor agonist, is currently under preclinical evaluation for cardiovascular indications.